These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 11160626)
1. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. Iwamura H; Suzuki H; Ueda Y; Kaya T; Inaba T J Pharmacol Exp Ther; 2001 Feb; 296(2):420-5. PubMed ID: 11160626 [TBL] [Abstract][Full Text] [Related]
2. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Ross RA; Brockie HC; Stevenson LA; Murphy VL; Templeton F; Makriyannis A; Pertwee RG Br J Pharmacol; 1999 Feb; 126(3):665-72. PubMed ID: 10188977 [TBL] [Abstract][Full Text] [Related]
3. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists. Raitio KH; Savinainen JR; Vepsäläinen J; Laitinen JT; Poso A; Järvinen T; Nevalainen T J Med Chem; 2006 Mar; 49(6):2022-7. PubMed ID: 16539390 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934 [TBL] [Abstract][Full Text] [Related]
6. Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Ueda Y; Miyagawa N; Matsui T; Kaya T; Iwamura H Eur J Pharmacol; 2005 Sep; 520(1-3):164-71. PubMed ID: 16153638 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101 [TBL] [Abstract][Full Text] [Related]
8. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Bingham B; Jones PG; Uveges AJ; Kotnis S; Lu P; Smith VA; Sun SC; Resnick L; Chlenov M; He Y; Strassle BW; Cummons TA; Piesla MJ; Harrison JE; Whiteside GT; Kennedy JD Br J Pharmacol; 2007 Aug; 151(7):1061-70. PubMed ID: 17549048 [TBL] [Abstract][Full Text] [Related]
9. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Bolognini D; Cascio MG; Parolaro D; Pertwee RG Br J Pharmacol; 2012 Apr; 165(8):2561-74. PubMed ID: 21615724 [TBL] [Abstract][Full Text] [Related]
10. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. Ueda Y; Miyagawa N; Wakitani K Life Sci; 2007 Jan; 80(5):414-9. PubMed ID: 17055000 [TBL] [Abstract][Full Text] [Related]
11. The tamoxifen derivative ridaifen-B is a high affinity selective CB Franks LN; Ford BM; Fujiwara T; Zhao H; Prather PL Toxicol Appl Pharmacol; 2018 Aug; 353():31-42. PubMed ID: 29906493 [TBL] [Abstract][Full Text] [Related]
12. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol. McMahon LR J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255 [TBL] [Abstract][Full Text] [Related]
13. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. Ross RA; Brockie HC; Fernando SR; Saha B; Razdan RK; Pertwee RG Br J Pharmacol; 1998 Nov; 125(6):1345-51. PubMed ID: 9863666 [TBL] [Abstract][Full Text] [Related]
14. Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. Savinainen JR; Kokkola T; Salo OM; Poso A; Järvinen T; Laitinen JT Br J Pharmacol; 2005 Jul; 145(5):636-45. PubMed ID: 15852035 [TBL] [Abstract][Full Text] [Related]
15. Direct Stimulatory Effects of the CB Ruz-Maldonado I; Atanes P; Huang GC; Liu B; Persaud SJ Cells; 2021 Mar; 10(3):. PubMed ID: 33809893 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. Ihenetu K; Molleman A; Parsons M; Whelan C Eur J Pharmacol; 2003 Mar; 464(2-3):207-15. PubMed ID: 12620515 [TBL] [Abstract][Full Text] [Related]
17. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Clayton N; Marshall FH; Bountra C; O'Shaughnessy CT Pain; 2002 Apr; 96(3):253-260. PubMed ID: 11972997 [TBL] [Abstract][Full Text] [Related]
18. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Maekawa T; Nojima H; Kuraishi Y; Aisaka K Eur J Pharmacol; 2006 Aug; 542(1-3):179-83. PubMed ID: 16824511 [TBL] [Abstract][Full Text] [Related]
19. Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. Ross RA; Gibson TM; Stevenson LA; Saha B; Crocker P; Razdan RK; Pertwee RG Br J Pharmacol; 1999 Oct; 128(3):735-43. PubMed ID: 10516656 [TBL] [Abstract][Full Text] [Related]
20. Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor. Zhang Y; Xie Z; Wang L; Schreiter B; Lazo JS; Gertsch J; Xie XQ Int Immunopharmacol; 2011 Sep; 11(9):1303-10. PubMed ID: 21539938 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]